Scott J. Rodig, Ph.D., M.D.
This page shows the publications co-authored by Scott Rodig and Keith Ligon.
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81.
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.